You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Bacterial pathogen distribution grouped by MRSA therapy

From: Application of a methicillin-resistant Staphylococcus aureus risk score for community-onset pneumonia patients and outcomes with initial treatment

  Overall (n = 80,330) MRSA therapy (n = 29,254) No MRSA therapy (n = 51,076) P-value*
Organism identified, % 10.3 13.9 8.2 < 0.0001
 Single organism identified 9.3 12.1 7.7 < 0.0001
 Multiple organisms identified 1.0 1.9 0.5 < 0.0001
Gram-positive pathogens, %
Streptococcus pneumoniae 2.8 2.7 2.9 0.0571
Streptococcus, other 0.4 0.5 0.4 0.0270
Staphylococcus aureus 5.1 8.7 3.1 < 0.0001
 MRSA 3.3 5.1 2.3 < 0.0001
Gram-negative pathogens, %
Klebsiella pneumoniae 0.7 1.0 0.6 < 0.0001
Pseudomonas spp. 1.5 1.9 1.2 < 0.0001
Haemophilus influenzae 0.8 0.5 0.9 < 0.0001
Escherichia coli 0.2 0.4 0.2 < 0.0001
 Other gram-negatives 0.5 0.6 0.4 0.0007
Atypical pathogens, %
Mycoplasma pneumoniae < 0.1 < 0.1 0.1 0.0839
Legionella spp. 0.1 0.2 0.1 0.2029
Chlamydia spp. < 0.1 <0.1 < 0.1 0.7561
Anaerobes, % 0.1 0.1 0.1 0.0139
  1. MRSA Methicillin-resistant Staphylococcus aureus
  2. * Comparison between “MRSA therapy” versus “no MRSA therapy” groups